Experimental cancer treatments

Biotech Brief: Why Oncolytic Viruses are Becoming a Potent Weapon Against Cancer

Tuesday, March 24, 2020 - 12:30pm

PALM BEACH, Florida, March 24, 2020 /PRNewswire/ -- Oncolytic viruses are becoming a new class of cancer immunotherapy weapons to combat cancer.

Key Points: 
  • PALM BEACH, Florida, March 24, 2020 /PRNewswire/ -- Oncolytic viruses are becoming a new class of cancer immunotherapy weapons to combat cancer.
  • These naturally occurring or modified viruses are a potent new weapon against cancer, according to recent reports on this growing market.
  • Oncolytic viruses are naturally occurring or genetically modified to target specific types of cancer cells.
  • The oncolytic viruses must be genetically stable and be incapable of reverting back to its wild-type form while replicating inside cancer cells.

Biotech Brief: Why Oncolytic Viruses are Becoming a Potent Weapon Against Cancer

Tuesday, March 24, 2020 - 12:30pm

PALM BEACH, Florida, March 24, 2020 /PRNewswire/ -- Oncolytic viruses are becoming a new class of cancer immunotherapy weapons to combat cancer.

Key Points: 
  • PALM BEACH, Florida, March 24, 2020 /PRNewswire/ -- Oncolytic viruses are becoming a new class of cancer immunotherapy weapons to combat cancer.
  • These naturally occurring or modified viruses are a potent new weapon against cancer, according to recent reports on this growing market.
  • Oncolytic viruses are naturally occurring or genetically modified to target specific types of cancer cells.
  • The oncolytic viruses must be genetically stable and be incapable of reverting back to its wild-type form while replicating inside cancer cells.

DGAP-News: Abivax 2019 Financial Results and Operations Update

Monday, March 16, 2020 - 7:01pm

The observations confirmed the preliminary positive results on safety and tolerability of ABX464 along with a first evidence of its excellent long-term efficacy.

Key Points: 
  • The observations confirmed the preliminary positive results on safety and tolerability of ABX464 along with a first evidence of its excellent long-term efficacy.
  • Based on the encouraging results from the Phase 2a induction and maintenance trials, Abivax initiated a Phase 2b study, ABX464-103, in UC and enrolled the first patient in August 2019.
  • Top line results from this trial are expected in Q4 2020.
  • Abivax is currently planning for a start of the enrollment of patients in the second half of 2020.

EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance

Tuesday, March 3, 2020 - 2:00pm

Cancer cells overexpress TGF-, an immunosuppressive protein, to circumvent or thwart immune surveillance and cancer immunotherapy.

Key Points: 
  • Cancer cells overexpress TGF-, an immunosuppressive protein, to circumvent or thwart immune surveillance and cancer immunotherapy.
  • "The clearance of our IND is a major milestone for EpicentRx and the first of many oncolytic adenoviruses that are planned for development," said Tony R. Reid, M.D., Ph.D., Chief Scientific Officer of EpicentRx.
  • The candidate has been evaluated in multiple clinical studies, including the ongoing Phase 3 REPLATINUM trial for the treatment of SCLC.
  • For more information, please visit www.epicentrx.com and follow EpicentRx on Twitter and LinkedIn .

BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses

Tuesday, March 3, 2020 - 8:04am

BT-001 is a multifunctional oncolytic virus being co-developed by Transgene and BioInvent.

Key Points: 
  • BT-001 is a multifunctional oncolytic virus being co-developed by Transgene and BioInvent.
  • It is based on Transgene's Invir.IO platform and patented, large-capacity VVcopTK-RR- oncolytic virus.
  • "With BT-001, we are looking to combine Transgene's potent oncolytic virus with the local production of a high concentration of an anti-CTLA4 antibody.
  • With its proprietary platform Invir.IO, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses.

BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses

Tuesday, March 3, 2020 - 8:02am

BT-001 is a multifunctional oncolytic virus being co-developed by Transgene and BioInvent.

Key Points: 
  • BT-001 is a multifunctional oncolytic virus being co-developed by Transgene and BioInvent.
  • It is based on Transgene's Invir.IO platform and patented, large-capacity VVcopTK-RR- oncolytic virus.
  • "With BT-001, we are looking to combine Transgene's potent oncolytic virus with the local production of a high concentration of an anti-CTLA4 antibody.
  • With its proprietary platform Invir.IO, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses.

Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses

Tuesday, March 3, 2020 - 7:30am

BT-001 is a multifunctional oncolytic virus being co-developed by Transgene and BioInvent.

Key Points: 
  • BT-001 is a multifunctional oncolytic virus being co-developed by Transgene and BioInvent.
  • It is based on Transgenes Invir.IO platform and patented, large-capacity VVcopTK-RR- oncolytic virus.
  • BT-001 has been engineered to encode a Treg-depleting, anti-CTLA4 antibody derived from BioInvents proprietary n-CoDeR/F.I.R.S.T platforms, as well as the cytokine GM-CSF.
  • With BT-001, we are looking to combine Transgenes potent oncolytic virus with the local production of a high concentration of an anti-CTLA4 antibody.

Calidi Biotherapeutics Announces Appointment of Dr. George Peoples, a Prominent Immuno-Oncology Expert, to its Scientific and Medical Advisory Board

Thursday, February 27, 2020 - 10:00am

Calidi Biotherapeutics , Inc. (Calidi), a clinicalstage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of COL (retired) George E. Peoples, MD, FACS to its Scientific and Medical Advisory Board .

Key Points: 
  • Calidi Biotherapeutics , Inc. (Calidi), a clinicalstage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of COL (retired) George E. Peoples, MD, FACS to its Scientific and Medical Advisory Board .
  • Peoples is a passionate leader with significant experience in cancer vaccines and a recognized authority on early oncology therapeutic development.
  • I am excited to join this incredibly focused and dedicated group of advisors, said Dr. George Peoples, MD, FACS.
  • Calidi Biotherapeutics does not make any representation or warranty, express or implied, as to the completeness or updated status of such statements.

Global Markets for Cell Therapies & Oncolytic Virus, Forecast to 2026 - Covering Melanoma, Breast, Ovarian & Prostate Cancer Applications

Thursday, February 20, 2020 - 6:45pm

DUBLIN, Feb. 20, 2020 /PRNewswire/ -- The "Global Cell Therapies & Oncolytic Virus Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 20, 2020 /PRNewswire/ -- The "Global Cell Therapies & Oncolytic Virus Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cell Therapies & Oncolytic Virus market is growing at a CAGR of 17.32% from 2018 to 2026.
  • Factors such as rise in technological advancements and increase in usage of combination therapies are driving the market growth.
  • Increasing prostate cancer cases are also leading to the strong growth rate in prostate cancer therapies in recent years which is driving the market growth.

Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study

Wednesday, February 19, 2020 - 1:00pm

Additional endpoints include overall response rate (ORR), progression free survival (PFS), median overall survival (OS) and other markers of efficacy.

Key Points: 
  • Additional endpoints include overall response rate (ORR), progression free survival (PFS), median overall survival (OS) and other markers of efficacy.
  • The Phase 1 multicenter, open-label, dose-escalation study is designed to evaluate the safety and tolerability of CLR 131 administered as a 30-minute I.V.
  • The companys lead PDC therapeutic, CLR 131, is currently in three clinical studies - one Phase 2 study, and two Phase 1 studies.
  • The company is also conducting a Phase 1 dose escalation study in patients with r/r multiple myeloma and a Phase 1 study in pediatric solid tumors and lymphomas.